NCRP

PAC 1: Basic Criteria, Epidemiology, Radiobiology, and Risk

PAC 1 Publications


PAC Meeting, March 5, 2017
L to R / Standing: Ann Kennedy, Edouard Azzam, David Pawel, Joel Bedford, Sally Amundson, Michael Weil, Michael Story, Evagelia Laiakis, Amy Kronenberg, Polly Chang
Seated: Gayle Woloschak (SVP), Roy Shore, Jonine Bernstein (Co-Chair), Jacqueline Williams

PAC 1 oversees work on basic criteria, epidemiology, radiobiology, and risk. Within the scope of PAC 1 are four scientific committees (SC):

PAC 1 ties together several scientific disciplines which lay the technical foundation for decision making in radiological protection and regulation. Basic criteria involve understanding, describing and modeling the fundamental physical interactions of radiation with humans. Radiobiology is part of the basic criteria but also extends the science to in vitro studies of human cells and animal studies with the objective of translating results back to human outcomes. Risks are outcomes that can be measured or validated with epidemiology and predicted or extrapolated through modeling. These disciplines depend on each other to advance the state of knowledge with the ultimate goal of providing better technical guidance for the justification, optimization and limitation of radiation exposure.

In the fourth quarter of 2013, a proposal for writing a commentary, Guidance on Radiation Dose Limits for the Lens of the Eye, was sent to the BOD and approved, resulting in the formation of SC 1-23.

Also in the fourth quarter of 2013, a scientific committee was proposed (SC 1-24) for the writing of a report on radiation exposure in space and the potential for central nervous system (CNS) effects. The proposal and Committee members for this commentary were approved by the BOD in March of 2014. SC 1-24 was published as Commentary No. 25 on February 29, 2016.

PAC 1 met on Sunday, March 15, 2015 in conjunction with the NCRP 2015 Annual Meeting. The meeting started with a presentation by Dr. Dick Toohey to update the PAC on the WARP initiative (now CC 2) and discussion of that effort by members of PAC 1. The chairs/co-chairs or a representative of each of the active scientific committees under PAC 1 presented status reports on their committee activities.

Scientific Committee 1-22 (radiation protection for astronauts) has completed their work with the publication of Commentary No. 23 (November 2014). The report being drafted by SC 1-20 (with some members of PAC 6) is proceeding with expectation of a draft ready for PAC 1 and expert review early in June 2016. SC 1-21 was published as Commentary No. 24 on October 27, 2015. SC 1-23 is revising their draft based on comments received during expert review.

PAC 1 will meet in conjunction with the 2016 Annual Meeting on April 11, 2016.

The membership of PAC 1 is:

Woloschak-G

GAYLE E. WOLOSCHAK

Woloschak-G

is a Professor of Radiation Oncology and Radiology at Northwestern University Feinberg School of Medicine in Chicago. She and her group have been involved in studies of molecular consequences of radiation exposure, late tissue effects associated with radiation, and the use of radiation-inducible nanomaterials for cancer imaging and therapy. Dr. Woloschak also teaches radiation biology to radiation oncology and radiology residents, cardiology trainees, and graduate students and manages the Advanced Grant Writing Workshop for the Radiological Society of North America (RSNA).

She earned her PhD in medical sciences from the University of Toledo (Ohio) and did post-doctoral studies in molecular biology at the Mayo Clinic. She has served on review panels for various federal agencies including the National Institutes of Health, the National Aeronautics and Space Administration, the U.S. Department of Energy, RSNA, the U.S. Army Medical Research and Materiel Command, and others. She is currently an associated editor for Radiation Research, the International Journal of Radiation Biology, PLOS One, and Nanomedicine. She is a member of NCRP Program Area Committee 1, has served on organizational committees for several NCRP meetings, and has been involved in committees for several NCRP reports. She is currently Vice-President Elect for the Radiation Research Society.

gayle e. woloschak, Vice President
Bernstein

JONINE BERNSTEIN

Bernstein

is an Attending Epidemiologist at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City. Her core research focus is on breast cancer and gliomas and on understanding cancer risk and progression in order to identify those at highest risk because of gene carrier status, environmental exposures, or a combination of both. Dr. Bernstein is the Principle Investigator of the National Cancer Institute (NCI)-funded international 24-center Women's Environmental Cancer Radiation and Epidemiologic (WECARE) Study which was specifically designed to examine the interaction of radiation exposure and genetic predisposition in breast cancer, especially radiation-associated contralateral breast cancer (CBC) among 3,700 women with CBC and unilateral breast cancer.

The WECARE Study has served as the source population for studies of candidate genes such as BRCA1, BRCA2, CHEK2, and ATM, candidate gene pathways of DNA damage response involved in radiation-induced double-strand break repair—ATM, CHEK2, P53 binding protein (53BPI), and MDC1, Mre11, Rad50, and Nbs1 (e.g., MRN nuclease complex), a genome-wide association study, and most recently mammographic density. The global hypothesis across these studies is that women who carry certain types of mutations will be more susceptible to breast cancer than noncarriers, and possibly to radiation-associated breast cancer. Dr. Bernstein currently serves as a member of the Board of Directors of the American College of Epidemiology, the External Advisory group for the NCI-sponsored Breast Cancer Family Registry, the National Council on Radiation Protection and Measurements, and most recently the NCI Board of Scientific Counselors-Clinical Sciences and Epidemiology.

For the past two years, she has served on the Organizing Committee of the American Statistical Association Conference on Radiation and Health (2012 and 2014 meetings), and was Co-Chair of the Third North American Congress of Epidemiology, held in June 2011 for which she was honored by the 2012 ACE Award for Leadership and Service in Epidemiology. Dr. Bernstein holds a PhD in Epidemiology from Yale University, an MS in Applied Biometry from the University of Southern California, and an AB from Brown University. Before joining the faculty at MSKCC, she was Deputy Director of the Division of Epidemiology at Mount Sinai School of Medicine.

jonine bernstein, Co-Chair
Amundson-S

SALLY A. AMUNDSON

Amundson-S

is an associate professor of radiation oncology in the Center for Radiological Research at the Columbia University Medical Center in New York. She holds a doctorate in radiation biology and cancer biology from the Harvard School of Public Health. Her research uses functional genomics approaches to study low dose radiation and bystander effects, unique effects of space radiation, and the development of gene expression approaches for radiation biodosimetry.

She is co-director of the Center for High-Throughput Minimally-Invasive Radiation Biodosimetry. Prior to joining the group at Columbia, Dr. Amundson worked on molecular radiation biology in the Division of Basic Science at the National Cancer Institute (NCI), where she helped to develop global gene expression profiling techniques, and where she was an adjunct investigator in the NCI Radiation Epidemiology Branch. She has served on the NCRP since 2004 and on the Science Advisory Committee of the Radiation Effects Research Foundation (RERF) in Hiroshima since 2009, chairing the RERF scientific review for 2012.

Dr. Amundson is an associate editor of Radiation Research, and has served on the organizing and program committees for numerous meetings, including two of the American Statistical Association Conferences on Radiation and Health, which aim to integrate radiation biology with epidemiology. She is a recipient of the Michael Fry Research Award from the Radiation Research Society (RRS), and she is also a member of the RRS Council.

sally a. amundson
Azzam-E

EDOUARD I. AZZAM

Azzam-E

Edouard I. Azzam is Professor in the Department of Radiology at Rutgers University - New Jersey Medical School. He received his doctoral degree in the field of radiation biology from the University of Ottawa (Canada) in 1995. From 1995 to 2000, he pursued post-doctoral studies at the Harvard School of Public Health under the mentorship of Professor John B. Little.

His research program has focused on elucidating the mechanisms underlying the biological effects of low doses/low fluences of ionizing radiations that differ in their biophysical characteristics. The goal is to elucidate the role of intercellular communication and oxidative metabolism in radiation-induced nontargeted effects and adaptive responses. The outcome of these investigations may be significant towards reducing the uncertainty associated with current models for predicting the long-term health risks of exposure to radiation. His studies have been funded by the National Institutes of Health, the National Aeronautics and Space Administration, and the U.S. Department of Energy; and they have resulted in the training of numerous students and post-doctoral fellows who remain engaged in unraveling the biochemical events underlying the responses of human cells to ionizing radiation.

edouard i. azzam
BedfordJ

JOEL S. BEDFORD

BedfordJ

is Professor of Environmental and Radiological Health Sciences at Colorado State University, and holds a joint faculty appointment in the University Graduate Program in Cell and Molecular Biology. He received a D. Phil. degree in Radiobiology from Oxford University. He then joined the faculty at Vanderbilt University in 1966 and was promoted to Associate Professor in 1971. In 1975 he moved to his present position at Colorado State University. His research has focused principally on cellular radiation biology, radiation cytogenetics, carcinogenesis, genetic factors altering susceptibility to radiation effects and cancer biology. His programs have been funded, without interruption, by the National Institutes of Health (NIH), the U.S. Department of Energy, and/or the National Aeronautics and Space Administration since 1966. He served as a regular member and Chairperson of the NIH Radiation Study Section, and as a Councilor, Associate Editor, and later as President of the Radiation Research Society. He has received various awards such as the Failla Award and the Excellence in Mentoring Award from the Radiation Research Society.

He was a regular member of the National Academies' Board on Radiation Effects Research, and then on the National Academies' Nuclear and Radiation Studies Board. He served a 5 y term on the Scientific Council of the Radiation Effects Research Foundation in Hiroshima, Japan, and is a member of NCRP. He is a member of NCRP Program Area Committee 1. Dr. Bedford has authored some 150 peer reviewed articles, including several book chapters, and is an inventor on two patents.

joel s. bedford
ChangPolly Y. Chang
Hamada

Nobuyuki Hamada

Hamadawas born in Japan in 1976 and received a BSc in radiological sciences from Ibaraki Prefectural University of Health Sciences in 1999. He earned his MSc and PhD in pharmaceutical sciences from Nagasaki University in 2001 and 2004, respectively. He was a visiting PhD student at the U.K. Gray Cancer Institute for six months in 2003. He was a postdoctoral fellow at the National Institute of Radiological Sciences and in Tohoku University Institute of Development, Aging and Cancer, and a Center of Excellence Associate Professor in Gunma University Graduate School of Medicine. In 2010, he joined Central Research Institute of Electric Power Industry (CRIEPI) as a Research Scientist.

For NCRP, he is a PAC 1 member and was a Consultant to Scientific Committee 1–23 in 2014 to 2017 that produced NCRP Commentary No. 26. For the International Commission on Radiological Protection (ICRP), he is a corresponding member of Task Group 102, was Assistant Scientific Secretary in 2014 to 2016 and Associate Editor for ICRP Publications 126 through 132. Besides various activities in NCRP and ICRP, he is Chair of Scientific Advisory Board for LDLensRad (the European CONCERT project on low dose radiation effects to the ocular lens), Associate Editor for the International Journal of Radiation Biology, Editorial Board Member for Mutation Research/Reviews in Mutation Research, and Editor for Radiation Protection and Environment. He was a member of the Expert Group on Radiation Protection Science for the Organization for Economic Co-operation and Development/Nuclear Energy Agency/Committee on Radiation Protection and Public Heath from 2013 to 2016 that produced NEA No. 7265 report.

Since 1998, he has been involved in various radiation effect studies such as on nontargeted effects, heavy-ion effects and tissue reactions (e.g., cataracts and circulatory disease). He has published 92 papers in peer-reviewed international journals since 2001, which have gained >2,200 citations, impact factor and CiteScore of >210, h-index of 29, i10-index of 52, and RG score of >42. He received the 2013 Michael Fry Research Award of the U.S. Radiation Research Society and 15 awards from Japanese societies since 2006.

Nobuyuki Hamada
Kennedy A

ANN R. KENNEDY

Kennedy A

is a Professor in the Department of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine and the Richard Chamberlain Professor of Research Oncology at the University of Pennsylvania. She received her PhD in Radiation Biology from Harvard University and remained at Harvard as a faculty member for many years before joining the faculty at the University of Pennsylvania. She has been performing research on mechanisms of carcinogenesis and cancer prevention for her entire career, with research investigations including studies on molecular mechanisms, animal studies, and human trials. Much of the work in the Kennedy laboratory has focused on the soybean-derived protease inhibitor known as the Bowman-Birk inhibitor (BBI). BBI was originally identified as a cancer preventive agent from in vitro studies, and was then shown to prevent the development of cancer in many different models of animal carcinogenesis.

BBI, as Bowman Birk Inhibitor Concentrate (BBIC), is now being evaluated as a human cancer chemopreventive agent and as a therapeutic agent for several different human diseases. Much of her recent effort has been aimed at developing countermeasures for radiation induced adverse health effects which could occur in astronauts during space travel. She is currently the Team Leader for the Radiation Effects Team of the National Space Biomedical Research Institute, as well as a Co-Team Lead of the Space Radiation Element of the Human Research Program at the National Aeronautics and Space Administration. Dr. Kennedy is an author of more than 265 scientific papers. She is currently a Distinguished Emeritus member of NCRP.

ann r. kennedy
No Image

AMY KRONENBERG

is a staff biophysicist at the Lawrence Berkeley National Laboratory (LBNL). Her research focuses on fundamental processes that may result in genomic change following exposure to sparsely or densely ionizing radiation. Her group has also addressed links between molecular mechanisms of DNA damage repair and programmed cell death. Dr. Kronenberg teaches radiation biophysics to students at the National Aeronautics and Space Administration Space Radiation Summer School. Dr. Kronenberg received her ScD in Cancer Biology from the Harvard School of Public Health. She has served on review panels for federal agencies and international scientific review panels. She is a senior editor for Radiation Research and is also a member of the editorial board of the Journal of Radiation Research (Japan). Dr. Kronenberg's activities with NCRP have included prior service on the Board of Directors, as a member or chair of the Nominating Committee, and as a member of several scientific committees. She was recently an invited speaker at the 2011 Annual Meeting and is currently a member of NCRP Program Area Committee 1.

amy kronenberg
LaiakisE

Evagelia C. Laiakis

LaiakisEis an Assistant Professor at Georgetown University in the Department of Biochemistry and Molecular and Cellular Biology. Her previous studies included nontargeted effects and perpetuation of the radiation induced genomic instability phenotype. Her ongoing work focuses on biodosimetry through systems biology approaches with emphasis on metabolomics in biofluids (urine, blood, saliva) and tissues, and both animal models and human populations. Additionally, she is investigating radiation related metabolic dysregulation related to different radiation qualities with regards to medical exposures and space radiation.

Dr. Laiakis completed her undergraduate studies at University of Maryland at College Park in Cell Biology and Molecular Genetics. She received her PhD from University of Maryland at Baltimore in Human Genetics and completed her postdoctoral fellowship at Georgetown University. She is also an alumna of the National Aeronautics and Space Administration Space Radiation Summer School at Brookhaven National Laboratory. Additionally, she serves as a member of the organizing committee for the “Nuclear Security Summit and Workshop,” a now annual event taking place at Georgetown University to bring together policy leaders, emergency preparedness and response planners, economists, scientists, and engineers to discuss issues associated with nuclear disasters.

Evagelia C. Laiakis
Little

Mark P. Little

Littleis a Senior Investigator with the National Cancer Institute, Radiation Epidemiology Branch (REB). He studied mathematics at Trinity College, Cambridge and obtained his doctorate in mathematics at New College, Oxford. Over the last two decades he has been analyzing cancer and cardiovascular disease risks in the Japanese atomic-bomb survivors, and in other irradiated populations and offspring. Dr. Little has explored mechanistic models of carcinogenesis and cardiovascular disease in populations exposed to ionizing radiation and cigarette smoke. His statistical interests also include the effects of measurement error on regression estimates. Previously, he worked in the Imperial College Department of Epidemiology and Biostatistics, and before that at U.K. National Radiological Protection Board (now part of the Public Health England). He has served as consultant to the United Nations Scientific Committee on the Effects of Atomic Radiation for the recently completed cancer epidemiology document, to the International Atomic Energy Agency, to the U.K. Committee on the Medical Aspects of Radiation in the Environment, and to NCRP Scientific Committee 1-21. In REB, Dr. Little is working on assessment of thyroid cancer risk in various cohorts of persons exposed as result of the Chernobyl nuclear reactor accident, on risks of various health endpoints in the U.S. cohort of radiologic technologists, on treatment-related second cancer risks in various populations, focusing on dose measurement error and gene-radiation interaction. He has a particular interest in risks at low doses and dose rates, specifically in relation to childhood leukemia and circulatory disease.

Mark P. Little
NelsonG

GREGORY A. NELSON

NelsonG

earned his BS in chemistry from Caltech and his PhD in Cell and Developmental Biology at Harvard Medical School in 1979 where his thesis work was on the genetics of sex determination and spermatogenesis in the nematode C. elegans. During a postdoctoral fellowship at Harvard he investigated regulation of cell surface distribution of immunoglobulin on lymphocytes and its control by the calcium regulator, calmodulin. He joined the Jet Propulsion Laboratory in 1982 where he became interested in the space radiation environment and developed C. elegans as a biodosimetry system for spaceflight applications. As principal investigator, he flew the nematode experiments using the European Space Agency's Biorack facility on shuttle missions STS-42 (1992) and STS-76 (1996). He has since participated in shuttle missions STS-108, -118 and -135 examining effects of spaceflight on the immune and nervous systems of mice as part of the commercial biotechnology technology mission experiments 1-3.

The spaceflight experiences led him to participate in a number of National Aeronautics and Space Administration (NASA) programmatic activities, including the design of a dedicated biological satellite (LifeSat) system. He joined Loma Linda University (LLU) in 1996 to direct its new radiobiology program and to develop the infrastructure needed to do space research with proton beams. As the LLU radiobiology program grew, he was able to maintain a modest research activity with C. elegans, and later began collaborations on projects that have investigated the effects of protons and charged particles on immune responses, thyroid cells in three-dimensional tissue models, microvasculature, and rodent behavior. More recently he served as principal investigator on two NASA program projects (NSCOR) team involving nine institutions that investigate how space-like radiation exposures produce time- and dose-dependent changes in the mouse brain.

He was a founding director of NASA's Space Radiation Summer School held at the Brookhaven National Laboratory and serves as a member of NCRP. He recently completed a NASA-funded study investigating genes regulating bystander effects in C. elegans in a study involving RNA interference screening and microbeam-based experiments in collaboration with Professors Leslie Braby and John Ford of Texas A&M University and was appointed Adjunct Professor of Nuclear Engineering at TAMU in 2008. Another ongoing study funded by the U.S. Department of Energy investigates the effects of low doses of gamma rays on adaptive immunity in the mouse. Dr. Nelson is currently Professor of Basic Sciences and Radiation Medicine at Loma Linda University.

gregory a. nelson
Pawel D

DAVID J. PAWEL

Pawel D

is Statistician in the U.S. Environmental Protection Agency (EPA) Office of Radiation and Indoor Air. His current focus is a reassessment of the EPA radiogenic cancer risk estimates. He is a co-author of the "Blue Book" on EPA's most recent radiogenic risk models and an EPA technical report on its assessment of risks from radon in homes. In 2003, as the second Beebe Fellow, he studied methods to improve cancer-specific radiogenic risk estimates at the Radiation Effects Research Foundation (RERF) in Hiroshima, Japan and the National Cancer Institute in 2004.

Dr. Pawel was a member of the RERF Statistics Department from 1992 to 1994. He is a member of NCRP and served on its committee on uncertainties in internal dose estimates. He has a BS in Mathematics from the College of William and Mary, an MS in Statistics from Rutgers University, and a PhD in Statistics from the University of Wyoming.

david j. pawel
Sgouros G

GEORGE SGOUROS

Sgouros G

is Professor of Radiology, Oncology and Radiation Oncology, Director of Radiopharmaceutical Dosimetry Section of the Division of Nuclear Medicine, Johns Hopkins University, School of Medicine. He has been principal investigator or program leader on numerous grants with over 20 y experience in modeling and dosimetry of internally administered radionuclides with a particular emphasis on patient-specific dosimetry, alpha-particle dosimetry, and mathematical modeling of radionuclide therapy. Dr. Sgouros' laboratory is currently engaged in preclinical research investigating targeted alpha-emitter therapy of metastatic cancer. He is author on more than 100 peer-reviewed articles, as well as several book chapters and review articles. He is chairman of the Medical Internal Radionuclide Dose Committee of the Society of Nuclear Medicine, as well as steering committee member, of the American Association of Physicists in Medicine, Task Group on Internal Emitter Dosimetry.

He has served as chairman of the Dosimetry and Radiobiology Panel at a U.S. Department of Energy Workshop on alpha-emitters in medical therapy and, in the early 1990s, provided the physics/dosimetry support for the first Food and Drug Administration-approved human trial of targeted alpha-emitter therapy. He is also a member of the scientific advisory board of AREVA Med (Bethesda, Maryland), which is developing 212Pb-based alpha-emitters for targeted cancer therapy. Program areas of interest: medicine; dosimetry and measurement; education, risk communication, and outreach.

george sgouros

ROY E. SHORE

was a Professor and Chief of the Epidemiology Division at New York University School of Medicine before going to the Radiation Effects Research Foundation (RERF) in Hiroshima-Nagasaki as Vice Chairman and Chief of Research. He is an author of ~100 radiation-related publications and is currently working with other RERF investigators on studies of radiation and various diseases.

He has served on numerous governmental and scholarly committees, including as a long-time member of the International Commission on Radiological Protection and NCRP, and has served on various committees or task groups for the United Nations Scientfic Committee on the Effects of Atomic Radiation, the World Health Organization, the National Academy of Sciences, the National Cancer Institute, and the U.S. Environmental Protection Agency, among others. His interests include the effects of radiation on both cancer and noncancer disease incidence, and understanding the epidemiologic and biological modification of radiation effects by various environmental, genetic and age factors.

roy e. shore
StoryM

MICHAEL D. STORY

StoryM

is a professor at the University of Texas (UT) Southwestern Medical Center, Dallas. Dr. Story earned his PhD from Colorado State University. He holds the David M. Pistenmaa, M.D., Ph.D. Distinguished Chair in Radiation Oncology, serves as Vice-Chair of the Department of Radiation Oncology, Chief of the Division of Molecular Radiation Biology, and Director of the Genomics Shared Resource of the Simmons Cancer Center. Dr. Story also serves on the editorial board of the International Journal of Particle Therapy and has served on a number of review panels for the National Cancer Institute (NCI), the National Aeronautics and Space Administration (NASA), and other entities. He also serves as a member of the Scientific Advisory Board for Galera Therapeutics.

Dr. Story has taught for several sessions of the NASA Space Radiation Summer School, directs the radiobiology course for the radiation oncology resident program, and lectures in 'omics technologies for the Graduate School of Biological Sciences at UT Southwestern. Dr. Story's research is focused on four areas associated with radiation exposure. The first area is the identification of genomic or epigenomic factors that predict or are prognostic for the radioresponse in head and neck squamous cell carcinoma. The second area is the combinatorial application of radiation with other biologic- or chemo-agents, as well as low frequency electromagnetic fields to alter the response of both tumors (radiosensitization) or normal tissues (radioprotection).

The third area is characterizing the radioresponse of lung and liver tissues to high linear-energy transfer radiation exposures, including the development of biomarkers of carcinogenic risk in these tissues. Lastly, Dr. Story is heading the development of research programs in charged particle radiotherapy at UT Southwestern. Dr. Story's research is funded by the NCI, NASA, the Cancer Prevention and Research Institute of Texas, and industry.

michael d. story
Stram D

DANIEL O. STRAM

Stram D

is Professor in the Department of Preventive Medicine at the Keck School of Medicine of the University of Southern California. He received his PhD in statistics from Temple University in 1983 and served as a postdoctoral fellow in the Biostatistics Department of the Harvard School of Public Health from 1984 to 1986. From 1986 to 1989 he was a research associate at the Radiation Effects Research Foundation in Hiroshima, Japan.

Dr. Stram's main areas of research are in the statistical problems that arise in the design, analysis and interpretation of epidemiological studies of cancer and other diseases. His work on radiation epidemiology studies includes: (1) helping to characterize the statistical nature of errors in dose estimates for the atomic-bomb survivor study, (2) developing a multi-level variance components model for the dosimetry used in the Colorado Plateau uranium miners cohort for the purpose of better understanding dose and dose-rate effects in those data, and (3) characterizing study power and sample size issues in epidemiologic studies in which a complex dosimetry system is used to estimate radiation dose. Besides the field of radiation epidemiology his past and current research has focused on statistical issues relevant to clinical trials of treatment for pediatric cancer, nutritional epidemiology studies, and to studies of the genetics of complex diseases. He is an elected fellow of the American Statistical Association and has authored or co-authored over 200 peer reviewed articles.

daniel o. stram
WeilM

MICHAEL M. WEIL

WeilM

is a professor in the Department of Environmental and Radiological Health Sciences at Colorado State University (CSU). His research, which takes advantage of murine models of radiation carcinogenesis and leukemogenesis, is focused on understanding how radiation exposure can lead to cancer and why some individuals may be more susceptible than others. At CSU, Dr. Weil teaches a graduate level course in cancer genetics and lectures in courses on cancer biology, environmental carcinogenesis, principles of radiation biology, and the pathobiology of laboratory animals.

Dr. Weil earned his PhD in Microbiology from the University of Texas at Austin and was trained in cancer genetics and radiation biology in the Department of Biochemistry and Molecular Biology Biochemistry and the Department of Experimental Radiotherapy at the University of Texas M.D. Anderson Cancer Center. Dr. Weil is a Radiation Research Society council member and has served on National Institutes of Health, U.S. Department of Defense, and National Aeronautics and Space Administration grant review panels.

michael m. weil
Williams J

JACQUELINE P. WILLIAMS

Williams J

completed her undergraduate degrees at the University of Nottingham, followed by her post-doctoral training in radiation biology at St. Bartholomew's Hospital, University of London, U.K. Shortly after completing her studies, she joined the faculty at the University of Rochester, New York, in the department of Radiation Oncology, and recently in the department of Environmental Medicine. Since that time, Dr. Williams has accrued more than 25 y of experience in radiation biology and related fields and has been involved in a wide range of research areas, including clinically-related oncologic studies and clinical trials, tumor blood flow studies, long-term carcinogenic studies, and pharmacological and toxicological projects.

Her current research interests involve identifying mechanisms that underlie the initiation and progression of radiation-induced late normal tissue effects as a consequence of high-dose clinical treatment/accidental exposures or the lower doses associated with either space travel or mass exposures with the goal of developing protection or mitigation strategies. Dr. Williams has served as the President of the Radiation Research Society, the Research Chair on the Board of the American Society for Radiation Oncology, and has been elected to, and is currently serving as, Council Member to the International Association for Radiation Research.

jacqueline p. williams
 
BoiceJ

JOHN D. BOICE, JR.

BoiceJ

is the President of the National Council on Radiation Protection and Measurements (NCRP), Bethesda, Maryland, and Professor of Medicine at Vanderbilt University School of Medicine, Nashville, Tennessee. He is an international authority on radiation effects and currently serves on the Main Commission of the International Commission on Radiological Protection and as a U.S. advisor to the United Nations Scientific Committee on the Effects of Atomic Radiation. During 27 y of service in the U.S. Public Health Service, Dr. Boice developed and became the first chief of the Radiation Epidemiology Branch at the National Cancer Institute.

Dr. Boice has established programs of research in all major areas of radiation epidemiology, with major projects dealing with populations exposed to medical, occupational, military and environmental radiation. These research efforts have aimed at clarifying cancer and other health risks associated with exposure to ionizing radiation, especially at low-dose levels. Boice's seminal discoveries and over 460 publications have been used to formulate public health measures to reduce population exposure to radiation and prevent radiation-associated diseases.

He has delivered the Laurison S. Taylor Lecture at the NCRP and the Fessinger-Springer Lecture at the University of Texas at El Paso. In 2008, Dr. Boice received the Harvard School of Public Health Alumni Award of Merit. He has also received the E.O. Lawrence Award from the Department of Energy — an honor bestowed on Richard Feynman and Murray Gell-Mann among others — and the Gorgas Medal from the Association of Military Surgeons of the United States. In 1999 he received the outstanding alumnus award from the University of Texas at El Paso (formerly Texas Western College). Dr. Boice directs the Million U.S. Radiation Workers and Veterans Study to examine the lifetime risk of cancer following relatively low-dose exposures received gradually over time.

john d. boice, jr., NCRP Contact

Meetings:

Back to Top
Last modified: March 17, 2017